Kaufman C L, Ildstad S T
Institute for Cellular Therapeutics.
Neurochem Res. 1999 Apr;24(4):537-49. doi: 10.1023/a:1022587914079.
Bone Marrow Transplantation (BMT) is currently the most physiologic treatment for some types of leukodystrophies. In enzyme deficiency states, replacement of defective genes with cells carrying "normal" copies of these genes offers a natural form of gene therapy. This review will cover the various disease states which may be treated using bone marrow transplantation as well as the obstacles and advantages offered by this treatment modality. The potential for mixed hematopoietic chimerism, with reference to the advantages and disadvantages of treating various leukodystrophies, is reviewed. Finally, certain approaches which would reduce the morbidity and mortality associated with conventional BMT are discussed. If these obstacles can be overcome, BMT may offer the hope of cure to a number, but certainly not all, leukodystrophies.
骨髓移植(BMT)目前是治疗某些类型脑白质营养不良最符合生理的方法。在酶缺乏状态下,用携带这些基因“正常”拷贝的细胞替换缺陷基因提供了一种天然的基因治疗形式。本综述将涵盖可使用骨髓移植治疗的各种疾病状态,以及这种治疗方式所带来的障碍和优势。本文回顾了混合造血嵌合体的潜力,以及治疗各种脑白质营养不良的优缺点。最后,讨论了某些可降低传统骨髓移植相关发病率和死亡率的方法。如果这些障碍能够被克服,骨髓移植可能为一些(但肯定不是所有)脑白质营养不良患者带来治愈的希望。